Healthcare and Life Sciences Leadership Summit: Strategy & Innovation

Neill Jakobe, Vice Chair, Ropes & Gray

Neill Jakobe is vice chair of Ropes & Gray and a member of the firm’s management committee. He previously served as co-head of the firm’s global private equity practice and as managing partner of the Chicago office. Focusing on private equity buyouts and strategic M&A, Neill has helped steer an international roster of private equity and strategic clients through complex deals ranging in size up to billions of dollars.

Tim McCrystal, Partner & Co-Chair, Health Care Practice, Ropes & Gray

Tim McCrystal is the co-chair of the healthcare practice group. Tim has over thirty years of experience advising health care and life sciences companies and investors on complex and innovative matters, from unprecedented and innovative models of care delivery to highly complicated and unique transactions. Tim has negotiated numerous health care affiliations, mergers and acquisitions, joint ventures, hospital-physician relationships, medical practice acquisitions, formation and reorganization of multi-institutional health care systems. Tim has also been advising clients on novel regulatory issues related to the expansion of telehealth and the use of data and artificial intelligence to improve access to care.

Michael Beauvais, Partner & Chair, Strategic Transactions Practice, Ropes & Gray

Michael Beauvais, the immediate past global co-chair of the life sciences and health care industry group, has more than 25 years of experience representing clients in the pharmaceutical, biotechnology, medical device, digital health and health care services industries. His transactional experience spans a broad range of mergers and acquisitions, securities offerings, financings, collaborations, and other commercial transactions. Michael also regularly counsels private equity firms, financial sponsors and other strategic investors in the life sciences and health care industries on matters pertaining to their investments.

Robert Langer, Institute Professor, MIT and Co-founder, Moderna

Robert Langer is one of 9 Institute Professors at MIT; being an Institute Professor is MIT’s highest honor. His articles have been cited over 455,000 times; his h-index of 331 is the highest of any engineer in history. His patents have licensed or sublicensed to over 400 companies; he is a cofounder of many companies including Moderna. He holds 45 honorary doctorates and has received over 220 awards, including both the United States National Medals of Science and Technology & Innovation (one of 3 living individuals to have received both honors), and has been elected to the National Academies of Medicine, Engineering, Sciences, and Inventors.

Michael Langer, Co-Founder and Managing Partner, T.Rx Capital

Michael Langer is the Co-Founder and Managing Partner of T.Rx Capital which is a fund specializing in investments in the creation, seed and Series A at the intersection of biology & technology. He was an Executive Producer for Superhuman Body, an IMAX feature narrated by Matthew McConaughey that explores the cutting edge of human enhancement and biotechnology. The project aimed to bring the public inside the breakthroughs shaping the future of medicine, performance, and longevity. Other films in the pipeline have similar goals.

Michael is also active on the non profit side. He serves on the Leadership Board at Beth Israel Deaconess Medical Center, the Global Board of Directors for MassChallenge, the Leadership Board at the Terasaki Institute for Biomedical Innovation and is the Senior Advisor of Special Projects at the Galenus Foundation. He previously co-founded the Young Coder's Society which teaches children how to code using Raspberry Pi's, served on the Board of Advisors at the Museum of Science and he was formerly a Young Leader at the Milken Institute and a World Economic Forum Global Shaper. Michael has a BA from Lehigh University in Science, Technology and Society with a Double Minor in Entrepreneurship and Sustainable Development.

Mike Mortimer, Managing Partner and Founder, GHO Capital

Mike is an experienced healthcare industry senior executive who brings a 30+ years track record in operational and management positions. In his former role as an Executive Vice President in the core leadership team at Quintiles (now IQVIA), Mike was instrumental to driving the international growth of a now leading global Clinical Research Organisation. Prior to Quintiles, Mike was a Senior Vice President at Charles Schwab, responsible for the global retail and internet organisations.

Mike currently sits on the boards of Alcami, Biocare Medical, Genesis, ClearView, Velocity, Envision, X-Chem, Ardena and Validant and has overseen successful exits from BioAgilytix, Quotient Sciences and Caprion Biosciences.

Craig Shepherd, Sr. Managing Director, Blackstone Life Sciences

M. Craig Shepherd is a Senior Managing Director in Blackstone Life Sciences and a member of its Investment Committees. Since joining Blackstone in New York in 2017, Mr. Shepherd has played a leadership role in Blackstone’s acquisition of Clarus, the creation of Blackstone Life Sciences Yield, and Blackstone’s investments in Alnylam Pharmaceuticals, Axsome Therapeutics, Elanco (Tarsus royalties), Harmony Biosciences, PTC Therapeutics, Amicus Therapeutics, Sutro Biopharma (Vaxcyte royalties) and various others.

Prior to Blackstone, Mr. Shepherd worked at another life sciences private equity firm and at Amgen, where he held various roles at Amgen’s global HQ in California and its international HQ in Switzerland. Mr. Shepherd holds an MBA from Harvard Business School, a law degree from McGill University, and a BA from the University of Western Ontario. Mr. Shepherd has served on the boards of various business and non-profit organizations, including the Tufts University Parents Leadership Council, the American Kidney Fund, the Healthcare Advisory Board of the Partnership Fund for New York City and the McGill University Chancellor’s Advisory Board. A past recipient of the Terry Fox Humanitarian Award, Mr. Shepherd now serves on the program's board.

Tim McCrystal, Partner & Co-Chair, Health Care Practice, Ropes & Gray

David Ault, Counsel, Health Care, Ropes & Gray

David focuses his practice on advising complex health systems, health care providers and payers on the regulatory, contracting, compliance and litigation aspects of health insurance. He routinely advises clients on the analytical underpinnings of government health insurance models and regulations, the inner-workings of the regulatory bodies that develop these systems, as well as the compliance challenges and litigation risks that health insurance stakeholders face. David brings an insider’s understanding to the regulatory challenges and opportunities in the ever-changing health insurance space. A former government litigator and authority on alternative payment models under the Affordable Care Act (ACA), David now advises health care providers and payers on regulatory, compliance and litigation issues in health insurance, focusing on value-based contracting. He also provides counsel on complex issues arising from pharmaceutical manufacturer government price calculation and reporting practices.

Robert Bessler, M.D., CEO, Honest Health

Robert Bessler, M.D. is the Chief Executive Officer and a member of the Board of Directors at Honest Health, a physician-led value-based care enablement organization. With over two decades of experience in building and scaling healthcare companies, Dr. Bessler is recognized for his strategic vision and deep industry relationships.

In 2001, Dr. Bessler founded Sound Physicians, a multi-specialty medical group, where he served as CEO and Chairman for 22 years. Under his leadership, Sound Physicians grew from a start-up to a leading practice with more than 4,000 physicians and advanced practice providers, serving over 450 hospitals nationwide. His commitment to fostering an environment where clinicians could do meaningful work led to the organization’s expansion to over 5,000 clinical and business colleagues across 47 states.

Ronald J. Kuerbitz, CEO, ilumed

Ron is the CEO of ilumed, a leading Accountable Care Organization (ACO) participating in the Medicare REACH model. Under his leadership, ilumed has built a team and developed the systems to support over 600 physicians and 72,000 patients across 12 states. Before joining ilumed in 2024, Ron served as CEO of Upstream Rehabilitation, the largest provider exclusively focused on outpatient physical therapy in the United States. From 2017 to 2021, he was the founding CEO of agilon health, pioneering innovations in physician-led value-based care. Prior to that, he led Fresenius Medical Care North America (FMCNA) as CEO, overseeing the nation's foremost provider of renal products, pharmaceuticals, and services. In this role, he spearheaded FMCNA’s strategic transition from fee-for-service dialysis care to a population health management approach for individuals with renal disease.

With over 30 years of experience in health care, Ron has cultivated expertise across multiple sectors, including ambulatory and home-based services, laboratory, diagnostics and pharmacy services, physician practice management, government health plans, and pharmaceutical and medtech sales and manufacturing.

Glenn Pomerantz, M.D. J.D., EVP & Chief Medical Officer, Point32 Health

Glenn Pomerantz is chief medical officer at Point32Health and is responsible for leading and advancing the organization’s clinical capabilities. In this role he oversees, quality and accreditation, medical policy, utilization management, provider contracting and provider partnerships and the Harvard Pilgrim Health Care Institute, which includes the Department of Population Medicine at Harvard Medical School. Dr. Pomerantz previously served as chief medical officer at C2i Genomics, a company that monitors cancer with a blood test that can better determine treatment, progression and recurrence. Prior to joining C2i Genomics, Dr. Pomerantz served as senior vice president of health services at Gateway Health in Pittsburgh, where he developed a 3–5 year network and clinical excellence strategy, which exceeded all state value-based payment goals. He also served as chief medical officer at Blue Cross and Blue Shield of Minnesota and Horizon Blue Cross Blue Shield of New Jersey, and as national medical director at Aetna and Cigna. In addition, Dr. Pomerantz previously served as an instructor of medicine at Harvard Medical School and is spent thirteen years as a practicing physician. Dr. Pomerantz holds a Doctor of Law degree from Boston School of Law, a Doctor of Medicine degree from the University of Miami Miller School of Medicine and a Bachelor of Science in chemistry from the University of Miami. Dr. Pomerantz holds a faculty appointment in the Department of Population Medicine at Harvard Medical School.

Daniel Kraft, Physician-Scientist. Founder, NextMed Health & Digital.Health

Daniel is a Stanford and Harvard-trained physician-scientist, inventor, and entrepreneur focused on accelerating a much-improved future of health and biomedicine at the convergence of accelerating technologies and human innovation. He is trained in Internal Medicine & Pediatrics as well as hematology/oncology, stem cell transplantation, and aerospace medicine. He founded Exponential Medicine and NextMed Health (last held March 30-April 2, 2025) & Digital.Health. He chairs the XPRIZE Health Alliance, and is a sought-after speaker on the future of health and medicine, with 6 TED & TEDMED Talks.

Jennifer Romig, Partner, Health Care, Ropes & Gray

Jennifer has significant experience in advising clients on a variety of complex transactional, enforcement and regulatory matters within the health care and digital health industries. Jennifer advises health care industry clients, private equity firms and other investors on structuring and negotiating mergers and acquisitions, joint ventures, affiliations and a variety of contractual arrangements and general business transactions.

Jennifer has particular experience counseling clients on an array of data privacy, security and cybersecurity matters under HIPAA as well as state privacy and security laws. Jennifer regularly represents clients involved in security incidents and breaches involving protected health and other sensitive personal information, including in matters involving the United States Department of Health and Human Services, Office for Civil Rights and state authorities. Jennifer has also provided guidance to clients with respect to negotiation, implementation and adherence to Corporate Integrity Agreements.

David Cooney, Head of GTM Strategy, HelixAI

David Cooney is a growth and strategy leader with more than a decade of experience working with global drug and biotech companies to use AI to make research and development faster and smarter. He currently leads growth strategy at HelixAl, after a senior role at Causaly, where he refined company messaging, built relationships with senior leaders at major pharma companies, and built a multi million dollar sales pipeline for AI tools that support R&D.

Previously an Associate Partner at McKinsey & Company, David helped start and scale projects that applied AI across drug research, clinical trials, and commercial teams, advising CEOs and R&D leaders on practical ways to use data in everyday work. He began his career in healthcare strategy at Blue Latitude, where he helped open the U.S. office and plan launches for cancer medicines. David holds a master’s degree in Drug Discovery and Development from Imperial College London and is recognized for award winning team leadership and enterprise sales.

Daniel Kraft, Physician-Scientist. Founder, NextMed Health & Digital.Health

Edward Licitra, M.D., CEO of Astera Cancer Care and Board Member of One Oncology

Edward Licitra is an accomplished leader in the oncology sector, currently serving as a member of the Board of Directors at OneOncology and the Chief Executive Officer of Astera Cancer Care, both since April 2021. Edward's extensive experience includes positions on the Board of Directors for the Community Oncology Alliance and ION, as well as previous roles such as Board member at MMXPS MedMetrix Professional Services and Chairman of the Board at Regional Cancer Care Associates. Edward Licitra holds a Doctor of Philosophy in Biochemistry and Molecular Biology from the Massachusetts Institute of Technology, a Doctor of Medicine from Rutgers Robert Wood Johnson Medical School, and a Bachelor's Degree in Chemistry from the College of the Holy Cross.

Regina Sam Penti, Partner & Co-lead, AI Industry Group, Ropes & Gray

Regina Sam Penti is a partner and co-lead of Ropes & Gray’s artificial intelligence (AI) industry group. With an engineering foundation from MIT, Regina combines technical proficiency and legal acumen to empower life sciences and technology companies with strategic guidance on all aspects of deploying AI solutions—from licensing to implementation and governance. She also counsels clients—including Fortune 500 and emerging growth companies—on complex M&A, strategic collaborations, and the development, licensing, and commercialization of critical IP, data and technology assets.

Regina’s practice spans emerging technologies, including AI, digital health, platform technologies, fintech, semiconductors, robotics, biotech, and software. As a registered patent attorney, she is highly skilled in patent portfolio strategy, freedom-to-operate analyses, and patent disputes. She serves on the American Bar Association Task Force on AI and has held advisory roles with Law360. As co-founder and co-chair of the International IP Summit, she convenes global leaders to address issues in emerging technology law.

Seema Verma, Executive Vice President and General Manager, Oracle Health and Life Sciences

Seema Verma is the executive vice president and general manager of Oracle Health and Life Sciences, where she’s responsible for Oracle’s clinical and clinical trials applications portfolio. Shehas more than 25 years of experience leading transformative initiatives across the healthcare industry. In her current role, she’s spearheading the development of Oracle’s next-generation electronic health record system, transforming it into a clinical asset to help improve care delivery. She’s also focused on closing the gap between clinical research and clinical care to help improve patient outcomes.

She is currently a director on the board of LifeStance, a behavioral health company, and serves on the USC Price School Board of Councilors. She holds degrees from the University of Maryland and Johns Hopkins University School of Public Health.

Kellie Combs, Partner & Chair, Life Sciences Regulatory & Compliance, Ropes & Gray

Kellie Combs is the chair of the firm’s global life sciences regulatory and compliance practice group and a co-chair of the firm’s cross-practice digital health initiative. Kellie provides legal and strategic advice to pharmaceutical, biotechnology, medical device, food and cosmetic manufacturers, as well as health care providers and academic institutions, on a broad range of issues under the Food, Drug, and Cosmetic Act and the Public Health Service Act. She has extensive experience handling matters implicating FDA promotional rules and the First Amendment and also advises clients on FDA regulatory strategy, regulation of digital health tools, drug and biologic exclusivity, expedited development and approval programs, and post-approval compliance. In addition, she routinely conducts regulatory due diligence and negotiates key regulatory deal terms in connection with a wide variety of transactions involving drug, device, dietary supplement, cosmetic, and other consumer product manufacturers. She also regularly advises on administrative litigation and government enforcement matters involving FDA-regulated companies.

Kellie is ranked as a leading lawyer in the pharmaceutical and medical products space by Chambers USA, where she maintains a Band 1 ranking. Kellie takes a practical, solutions-oriented approach to counseling clients and has wide-ranging experience advising legal and business leaders at the world’s leading life sciences companies, in addition to early-stage companies.

Mark Barnes, Partner, Health Care, Ropes & Gray

Mark Barnes—named the 2019 Financial Times “Legal Innovator of the Year”—is a preeminent thinker and adviser to universities, medical centers, health care and life sciences companies, and investors. He has extensive experience guiding clients on legal issues related to research with humans and animals, research misconduct/research fraud, stem cell and genetic research, federal research grants and contracts, international research collaborations and “foreign influence” regulations, and data privacy.

Throughout his career, Mark has played a leadership role in the areas of clinical trials and data privacy. From 1999 to 2024, Mark served, first as a member and later as a subcommittee chair, of the HHS Secretary’s Advisory Committee on Human Subjects Protections (SACHRP), formerly known as the HHS National Human Research Protections Advisory Committee (NHRPAC). In 2012, with Dr. Barbara Bierer, Mark started, and continues to serve as faculty co-chair of, the Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard (MRCT Center), a project in which government, industry and academic medicine have partnered to improve the planning, conduct and regulation of multi-site, multi-national clinical trials. Much recent effort of MRCT Center has been devoted to clarifying the secondary research uses of personal data under the jurisdiction of the EU General Data Privacy Regulation (GDPR), about which Mark has published extensively, and to issues of national and international diversity in clinical trial planning and recruitment. The MRCT Center is now pioneering approaches to ensuring data integrity in the conduct of clinical trials and in bench science research, in reaction to increased public concerns about data integrity in science. Mark was a co-founder and founding board member of Vivli, a nonprofit that collects and shares participant-level anonymized data from clinical trials conducted by life sciences companies, hospitals and academic research institutions.

Margaux Hall, Partner, Health Care, Ropes & Gray

Margaux Hall is a partner in the firm’s nationally recognized health care practice, based in Washington, D.C. Margaux is a leading lawyer in drug pricing, market access and value-based arrangements. She brings to clients an understanding of the transformative legal and policy issues and market changes affecting pricing, reimbursement, coverage and access to drugs, vaccines and devices, including in the wake of the COVID-19 pandemic. Recognized by Chambers and other publications, Margaux provides sophisticated regulatory and strategic business counsel to clients – including pharmaceutical manufacturers, investors, and others – on matters involving coverage and reimbursement under Medicare Advantage-Part D, Medicaid, the Federal Supply Schedule, and other government programs; innovative contracting and payment arrangements under government and commercial contracts; and price reporting obligations under federal and state laws.

Margaux’s deep knowledge of the pharmaceutical supply chain also is invaluable in major life sciences transactions. Investors and others turn to Margaux to assist them in assessing and evaluating their investments in pharmaceutical products, specialty and long-term care pharmacies, pharmacy benefit managers, distributors, group purchasing organizations, and other companies providing services to entities in the supply chain.

Elizabeth Jurinka, Operating Director, Healthcare Policy, Vistria PRG

Prior to joining Vistria, Elizabeth spent nearly two decades in the White House and Congress, specializing in health care policy and strategy. Most recently, Elizabeth served in the White House as a Special Assistant to the President in the Office of Legislative Affairs where she worked with her colleagues to successfully promote and pass The American Rescue Plan (ARP), The Infrastructure Investment and Jobs Act (IIJA), and The Inflation Reduction Act (IRA). Prior to the White House, she served as Chief Health Advisor to Chairman Ron Wyden (D-OR) and the Senate Finance Committee where she oversaw the development and execution of key health care priorities within the Committee’s extensive health care jurisdiction of Medicare, Medicaid, and key components of the Affordable Care Act. In this role, Elizabeth was instrumental in developing the arguments and strategy used to successfully prevent repeal of the Affordable Care Act and spearheaded negotiations with the Committee Republicans on prescription drug pricing reform that later became the basis for policies passed in the Inflation Reduction Act. During her tenure on Capitol Hill, she also negotiated several other major health care bills including the repeal of the Sustainable Growth Rate, the longest CHIP extension since the program’s enactment, and chronic care reform, among others. Elizabeth is also a Senior Policy Fellow at Yale University’s Tobin Center for Economic Policy. Elizabeth received her B.A. from the University of Maryland and her M.A. in Government from Johns Hopkins University.

Karim Mikhail, Senior Advisor, Office of Commissioner, U.S. Food and Drug Administration Department of Health & Human Services

Karim Mikhail is a distinguished global pharmaceutical executive and entrepreneur with over two decades of leadership experience in transforming scientific innovation into viable commercial ventures. Currently serving as a Senior Advisor at the FDA in White Oak, Maryland, Mikhail brings extensive expertise in leading both large pharmaceutical companies and small biotechnology startups across therapy areas including cardio-metabolism, respiratory, immunology, neuroscience, oncology, women's health, and anti-infectives.

His clinical development experience spans cardiovascular, neuroscience, immunology, and oncology therapeutics, providing deep understanding of the drug development lifecycle from bench to bedside to market. His unique combination of entrepreneurial vision, global pharmaceutical expertise, and transformational leadership across both large corporations and emerging biotechnology companies positions him exceptionally well to advise the FDA through an important phase of reform and transformation. His deep understanding of the drug development ecosystem from multiple perspectives—regulatory, commercial, and scientific—coupled with his proven track record of navigating complex organizational changes, enables him to provide strategic counsel during this critical period of agency evolution and modernization.

Mikhail is an accomplished global corporate CEO with significant P&L operational experience for publicly listed companies, demonstrating proven revenue and EBITDA growth throughout his career. As Founder and CEO of THEODON, his strategic advisory firm, he advised institutional investors, global private equity firms, and life sciences companies on value creation initiatives. Mikhail holds a Master of Science in Biopharmaceutical Management from École supérieure de commerce de Paris (ESCP Business School) and a Bachelor of Pharmacy & Pharmaceutical Sciences from Cairo University.

Conor Sheehey, Director, Leavitt Partners

Conor Sheehey is a Director at Leavitt Partners, where he advises and assists a broad range of clients in navigating the complex and dynamic health policy landscape. Prior to joining Leavitt Partners, Conor served as Senior Policy Advisor to Senate Finance Committee Chairman Mike Crapo (R-ID). During his tenure on committee staff, Conor spearheaded bipartisan efforts to develop and advance comprehensive pharmacy benefit manager reform legislation, as well as prescription drug shortage mitigation and clinician payment reform proposals. He also played a leading role in successful bipartisan efforts to address mental health, expand telehealth, and promote innovative technologies. Additionally, Conor served as the lead Republican in presenting and litigating issues before the Senate Parliamentarian throughout the development and consideration of the Inflation Reduction Act's drug pricing provisions. Before joining committee staff, Conor spent four years in the Office of Senator Tim Scott (R-SC), ultimately serving as Deputy Legislative Director.

Prior to coming to Capitol Hill, Conor taught for three years as a Teach For America corps member in the Bronx, NY while earning his Master's degree. He received his B.A. from the University of Virginia, which he attended as a Jefferson Scholar.

Arthur Mok, Partner, Strategic Transactions, Ropes & Gray

Arthur Mok advises global leaders in the life sciences industry, with a specific emphasis on representing biotechs, multinational pharmaceutical companies and sector specialist investment sponsors on matters centered on Asia. Arthur is also a member of the firm’s management committee, previously served as the regional managing partner of the firm’s Asia offices and founded the firm’s Shanghai office.

Arthur is regularly called upon by C-suite executives, board members, M&A professionals, financial investors and advisors for his insight into the opportunities and challenges presented by the life sciences industry in Asia. His deep understanding of regional trends also makes him a trusted advisor to leaders in the field. Clients say that Arthur is a “great business adviser” with “excellent judgement,” as reported to Chambers Greater China Region, where Arthur is ranked Band 1. His work for investment sponsors has also resulted in his top rankings in the IFLR 1000.

Griffin Almy, Legal Director, Competition & Regulatory Affairs, EQT Group, New York

Griffin Almy joined EQT Legal in 2022 and is based in the New York office. Griff leads EQT's transaction regulatory capability, ensuring that all deals receive timely clearances - including Foreign Direct Investment, antitrust and others - and managing related issues for all EQT investments worldwide. Prior to joining EQT, Griffin worked as an antitrust attorney in the New York office of Skadden, Arps, Slate, Meagher and Flom, advising clients on the competition aspects of their high stakes transactions, investigations and litigations. Griffin holds a J.D. from the University of Virginia School of Law and a B.A. from the College of William & Mary.

Laura Murphy, Professor of Human Rights, Sheffield Hallam University and Carr-Ryan Center Fellow, Harvard Kennedy School

Laura Murphy is a Professor of Human Rights at Sheffield Hallam University in the UK where she conducts research in the field of trafficking, contemporary slavery, and forced labor globally. Laura is also Carr-Ryan Center Fellow at Harvard Kennedy School. where she writes policy relevant briefs encouraging the adoption of forced labor import bans globally. She also conducts research on forced labor in emerging technology and other critical materials supply chains.

Laura was a Biden administration appointee at the Department of Homeland Security, working on implementation of the Uyghur Forced Labor Prevention Act. Her research currently focuses on forced labor in China and in international supply chains. She has written several books on forced labor globally including Freedomville (Columbia Global Reports, 2021) and The New Slave Narrative (Columbia University Press).

Andrew O'Connor, Partner, Litigation & Enforcement, Ropes & Gray

Andrew O’Connor represents clients in high-stakes government investigations and civil litigation. He has represented many well-known companies facing major DOJ and state attorney general investigations, class actions, and False Claims Act litigation. He is co-leader of Ropes & Gray’s Health Care and Life Sciences Industry Group and co-heads the firm’s Chambers Band 1–ranked False Claims Act practice. He has a proven track record helping clients navigate high-profile legal matters.

Andrew recently played a leading role a multi-district litigation involving more than 3,000 state and federal cases across the country, culminating in a nationwide resolution with 50 state and territory attorneys general and hundreds of civil plaintiffs. His practice spans civil and criminal matters involving the False Claims Act, fraud statutes, anti-kickback laws, FDA regulations, data security and privacy, the Controlled Substances Act, antitrust laws, insurance billing rules, the Foreign Corrupt Practices Act, and other anti-fraud laws. Andrew has successfully litigated complex civil cases on behalf of clients in state and federal court, at both the district and appellate levels. He has played lead roles in defending clients against potential enforcement actions by the U.S. Department of Justice, state attorneys general, and federal regulatory agencies. He has also led internal investigations on a national and international scale.

Robert Silvers, Partner, Ropes & Gray

Robert Silvers is co-chair of the firm’s national security practice group and a member of its global data, privacy & cybersecurity practice. Rob is a globally recognized leader at the intersection of security, emerging technology, and law. Drawing on his senior-level experience at the U.S. Department of Homeland Security (DHS), he advises clients on cybersecurity, privacy, trade controls (CFIUS and forced labor enforcement), AI security and governance, and crisis management. He excels at navigating clients through parallel proceedings that accompany security issues, including internal and government-facing investigations, regulatory inquiries, litigation defense, and incident response and management. The perspective he brings as a former official in the top echelon of the U.S. government makes him a trusted advisor to boards of directors, senior officers, fund managers, and other clients. Clients value Rob’s practical advice and his intuitive sense of how government agencies will react to complex situations.